|
HOME | ABOUT | SERVICES | HEALTH INFO | RESEARCH | PATIENTS + VISITORS | CAREERS | MEDIA | SUPPORT WCH |
|
SA Maternal Serum Antenatal Screening (SAMSAS) ProgramSA PathologyGenetics & Molecular Pathology Directorate, WCH siteOutlineAim
| |||||||||||||||||||||||||
| 1st Trimester | Blood sample 10w0d –13w6d | *Optimal gestation 10 - 12 weeks |
| Ultrasound 11w0d – 13w6d | *Optimal gestation 11 - 12 weeks | |
* The blood sample and nuchal translucency measurement can be done on different days |
||
| 2nd Trimester | Blood sample 14w0d – 20w6d | *Optimal gestation 16 weeks |
Further information
Electronic reporting is available in various forms, please contact SAMSAS for options.
Reallocation of telephone codes for the Women’s and Children’s Hospital has resulted in the first four digits of the SAMSAS number to be changed to 8161-.
Our new numbers are: telephone: (08) 8161 7285 fax: (08) 8161 8085
Our new website address is: http://www.wch.sa.gov.au/samsas.html
Our e-mail address is: samsas.program@health.sa.gov.au
The following procedure will ensure the best results:
1. As soon as a patient decides she wants the screening test, arrange for the blood measurements.
2. A 5-10 mL clotted blood specimen is required. This can be taken at the same time as the antenatal serology specimen, on or after 14 weeks gestation. Your usual blood collection arrangements can be used. Your patient does not have to come to the Women’s and Children’s Hospital for this collection.
3. Use a SAMSAS request form (telephone (08) 8161 7285 if you require some of these, or download it from this site), or your regular pathology request form but specify "send to WCH".
(a) the test request is "second trimester screen";
(b) complete the gestational age information (weeks+days and date estimated, or EDD). This will be amended if necessary by SAMSAS when the ultrasound scan information is available;
(c) send the blood specimen to Women’s and Children’s Hospital.
Results
The blood results will be forwarded automatically to the requesting doctor. SAMSAS will be following the outcome of all screened patients through their usual audit procedures to ensure the continuation of effective screening practice.
Costs
Patients will receive an account from SA Pathology, IMVS for the blood measurements. This account will be fully covered by Medicare.
Further information
Electronic reporting is available in various forms, please contact SAMSAS for options.
Please don’t hesitate to call SAMSAS ((08) 8161 7285 or e-mail) if there are any concerns or questions you may have about SAMSAS antenatal screening services.
What is screening for Neural Tube Defects, Down syndrome and Trisomy 18?
What are Neural Tube Defects, Down syndrome and Trisomy 18?
What are the tests?
What can the tests tell?
What do ‘increased risk’ and ‘not at increased risk’ mean?
What are the further tests?
Must you have further testing?
Will the screening tests detect all afffected pregnancies?
What happens if your baby is found to have a Neural Tube Defect, Down syndrome or Trisomy 18?
Where can I get more information?
Spina Bifida and Hydrocephalus
Down Syndrome Society of South Australia Inc
Spina Bifida Association of Tasmania Inc
Telephone +61 3 6223 4537
Forms for ordering a maternal serum screening test are described in the section " How to access the service" above.
SAMSAS is pleased to announce we can now offer combined ultrasound+biochemical screening for fetal Down sydrome in first trimester. This service is offered in a collaboration between SAMSAS and a number of ultrasonology practices who can offer nuchal translucency measurements.
Medical literature indicates that this combined approach provides a greater detection of fetal Trisomy 21 (up to 90%) at a lower false positive rate (around 5%) than either serum biochemistry or early ultrasound screening can when used separately (see table). SAMSAS is collecting its data and working with other centres interstate to establish an Australian Standard for first trimester screening.
% Detected by |
|
| Serum biochemistry alone (4 analytes) | 70.1% |
| Ultrasound alone | 72.7% |
| Serum biochemistry + Ultrasound | 88.3% |
| Information from Cuckle & Van Lith (1999), Prenatal Diagnosis 19: 505-512 | |
For further information please see:
Second Trimester Screening (14 weeks to 20 weeks)
The following newsletters are PDF files, or Printable Document Format (for printing or viewing), you will need to have the free PDF plug-in before you can access the files.
What's in an "increased risk of Down syndrome" report?
What’s in an “increased risk of NTD” report ?
Update 9 for South Australia - July 2001
Welcome to First Trimester Screening
Locations for First Trimester Nuchal Translucency Scans in SA
Update 9 for Tasmania - October 2001
Welcome to First Trimester Screening
Locations for First Trimester Nuchal Translucency Scans in TAS
First Trimester Service
Box Plots of Affected Cases - First Trimester
Down Syndrome Audit First Trimester Screening
Age Specific Performance Data and Aid for Pre-Test Counselling
Trends in Maternal Serum Screening and Invasive Prenatal Testing in SA Following Introduction of First Trimester Combined Screening
Changes to Maternal Serum Screening
Nuchal Translucency Progress Report 1 - December 2001
Nuchal Translucency Progress Report 2 - May 2003
Nuchal Translucency Progress Report 3 - April 2004
Nuchal Translucency Progress Report 4 - April 2005
Nuchal Translucency Progress Report 5 - March 2006
Nuchal Translucency Progress Report 6 - February 2007
Nuchal Translucency Progress Report 7 - February 2008
Nuchal Translucency Progress Report 8 - February 2009
Trisomy 18 Discussion Paper April 2005
SA Maternal Serum Screening to date - March 2008
Trends in Screening for Down syndrome in South Australia 1995-2004 - Presentation SMFM (Abstract) 30, AJOG V195:6 Sup.S February 2007
Trends in Screening for Neural Tube Defects in South Australia 1986-2004 - Poster SMFM (Abstract) 643, AJOG V195:6 Sup.S February 2007
Biochemical Update Fetal Medicine Course - ASUM Presentation Sept 2005
1st and 2nd Trimester Markers and Pregnancy Outcome - ASUM Presentation Sept 2005
Screening for Down Syndrome - The Odds are with you - HGSA Fremantle Aug 2004
Performance of Second Trimester Maternal Serum Screening in South Australia - Aug 1998
ADAM12 A promising new maternal serum marker in screening for Down syndrome in both first and second trimesters of pregnancy. Poster
Robert Cocciolone, Renata Bird, Eva Martin, Diana Penhall, Lyn Raniolo (HGSA ASM, Adelaide SA, August 2008)
Combining first and second trimester markers for Down syndrome screening: Think twice
Robert Cocciolone, Kate Brameld, Peter O'Leary, Eric Haan, Peter Muller, Karen Shand Aust N Z J Obstet Gynaecol 2008; 48: 492-500
The definitive version of this paper is available at www.blackwell-synergry.com; http://www3.interscience.wiley.com/cgi-bin/fulltext/121476797/PDFSTART
Trends in state/population-based Down syndrome screening and invasive prenatal testing with the introduction of first-trimester combined Down syndrome screening, South Australia, 1995-2005
Muller PR, Cocciolone R, Haan EA, et al Am J Obstet Gynecol 2007;196:315.e1-315.e7. Editorial
Karyotypes found in the population declared at increased risk of Down syndrome following maternal serum screening
Richard G. Ryall et al. Prenatal Diagnosis 2001; 21: 553-557
The impact of maternal serum screening on the birth prevalence of Down’s syndrome and the use of amniocentesis and chorionic villus sampling in South Australia
Tracy Cheffins et al. British Journal of Obstetrics and Gynaecology December 2000, Vol 107, pp. 1453-1459
Improved performance in a prenatal screening programme for Down syndrome incorporating serum-free hCG subunit analyses
R.G. Ryall et al. Prenatal Diagnosis, Vol. 12, 251-261 (1992)
Epidemiology of Down syndrome in South Australia, 1960-89
Alan J. Staples et al. Am. J. Hum. Genet. 49:1014-1024, 1991
Monday to Friday 9am – 5pm
Supervising Technical Officer
Renata Bird
Technical Staff
Eva Martin
Lyn Raniolo
Telephone: (08) 8161 7285
Facsimile: (08) 8161 8085
Email: samsas.program@health.sa.gov.au
Robert Cocciolone
Telephone: (08) 8161 7285
Facsimile: (08) 8161 8085
Email: robert.cocciolone@health.sa.gov.au
South Australian maternal Serum Antenatal Screening (SAMSAS) Program
SA Pathology, Department of Genetics & Molecular Pathology
4th Floor Rogerson Building
Women’s & Children’s Hospital
72 King William Road
North Adelaide South Australia 5006
Phone : 08 8161 7285
Fax: 08 8161 8085
Email: samsas.program@health.sa.gov.au
| ^TOP | FEEDBACK |
SITE INDEX |
DISCLAIMER |
CONTACT |
COPYRIGHT |
PRIVACY Last Modified: 08-04-2009 16:19:49 |